Lisata Tender Offer Extended to July 16; 56% of Shares Tendered
LSTA sits 86% above its 52-week low of $1.81.
Summary
Lisata Therapeutics' tender offer has been extended to July 16, 2026, with 56% of shares tendered so far. The acquisition by Kuva Labs remains on track but faces continued delays.
Key Events · M&A and Partnerships · LSTA
-
Tender Offer Extended
The expiration of the tender offer has been extended to 11:59 p.m. on July 16, 2026, from the previous deadline of July 10, 2026.
-
56% of Shares Tendered
As of July 10, 2026, approximately 5,105,552 shares have been validly tendered, representing about 55.98% of the 9,119,742 outstanding shares.
-
Offer Price Remains $4.00 + CVRs
The offer price is $4.00 per share in cash plus one contingent value right (CVR) per share, which could pay up to an additional $3.00 per share upon achievement of milestones.
-
Closing Expected Promptly After Expiration
Parent and Purchaser expect the offer to be consummated promptly following the expiration, subject to remaining conditions.
Analysis · LSTA · Life Sciences
The tender offer for Lisata Therapeutics has been extended to July 16, 2026, with approximately 56% of outstanding shares already tendered. This is a critical update in the long-delayed acquisition by Kuva Labs, which has faced multiple failures to commence and close. The high tender rate suggests strong shareholder support, but the repeated extensions and going concern warning keep the outcome uncertain. If the offer closes, shareholders receive $4.00 per share in cash plus contingent value rights worth up to $3.00 per share.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 35.6% of the 1155 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LSTA was trading at $3.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.8M. The 52-week trading range was $1.81 to $5.07. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.